NHLBI Stops Enrollment in Study on Resuscitation Methods for Cardiac Arrest
Enrollment has ended early in a large, multicenter clinical trial comparing two distinct resuscitation strategies delivered by emergency medical service (EMS) providers to increase blood flow during cardiac arrest. The study's independent monitoring board and the National Heart, Lung, and Blood Institute (NHLBI), the lead sponsor of the study, stopped enrollment based on preliminary data suggesting that neither strategy significantly improved survival. One strategy compared different durations of manual cardiopulmonary resuscitation (CPR) by EMS providers before they assessed whether defibrillation was needed, and the other strategy tested the potential benefits and risks of an investigational device to maintain pressure in the chest during CPR.
FDA Warns Companies against Marketing Illegal Flavored Cigarettes
The U.S. Food and Drug Administration is enforcing the flavored cigarette ban provision of the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) by issuing several warning letters to companies continuing to sell illegal flavored cigarettes to consumers in the United States through their Web sites.
NIDA Launches New Substance Abuse Resources to Help Fill Gaps in Medical Education
The rigors of medical training sharpen a doctor's ability to diagnose and treat a wide variety of human afflictions. However, drug abuse and addiction are often insufficiently covered in medical school curricula, despite the fact that drug use affects a wide range of health conditions and drug abuse and addiction are themselves major public health issues.
Stiff Nights - product contains undeclared drug ingredient
Consumers warned that product sold as a dietary supplement contains sulfoaildenafil.
FDA and FSIS Collaborate To Improve Tracing of Unsafe Food Products
A joint public meeting focused on improving the system for tracing of food products and ingredients that are causing illness outbreaks or presenting other risks to the health of consumers was announced today by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services and the Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA).
FDA Warns Consumers on Sexual Enhancement Products
The U.S. Food and Drug Administration is warning consumers that Stiff Nights, a product marketed as a dietary supplement for sexual enhancement, contains an ingredient that can dangerously lower blood pressure and is illegal.
Researchers Discover Mutations in Two Genes that Cause Early-Onset Inflammatory Bowel Disease
An international team including researchers with the National Institutes of Health has discovered that mutations in either of two related genes cause a severe and rare form of inflammatory bowel disease (IBD) in young children.
NIAID Announces New Human Immunology Research Awards to Help Fight Emerging Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $208 million to two programs that support research to better understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism.
NIAID Awards Five-Year, $56 Million Contract to Continue Study of Asthma in Inner City Children
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has renewed the contract to continue studying asthma in children living in lower-income, inner city environments. This five-year, $56 million award will support the Inner-City Asthma Consortium (ICAC), a nationwide clinical trials network to evaluate promising new therapies to reduce asthma severity and prevent disease, and to perform basic research to understand how these therapies work.
NIH Awards More than 50 Grants to Boost Search for Causes, Improve Treatments for Autism
The National Institutes of Health has awarded more than 50 autism research grants, totaling more than $65 million, which will be supported with American Recovery and Reinvestment Act funds. These grants are the result of the largest funding opportunity for research on autism spectrum disorders (ASD) to date, announced in March 2009.